PPARγ ligand attenuates PDGF-induced mesangial cell proliferation: Role of MAP kinase

Kidney International

Volumn 64, Issue 1, 2003, Pages 52-62

  Ghosh, Siddhartha S ^a   Gehr, Todd W B ^a   Ghosh, Shobha ^a   Fakhry, Itaf ^a   Sica, Domenic A ^a   Lyall, Vijay ^a   Schoolwerth, Anton C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

AP 1; Ciglitazone; Cyclin D1; Decoy oligonucleotide

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CIGLITAZONE; CYCLIN D1; DECOY OLIGONUCLEOTIDE; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OLIGONUCLEOTIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLATELET DERIVED GROWTH FACTOR; PROTEIN P21; PROTEIN P27; ROSIGLITAZONE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TROGLITAZONE; UNCLASSIFIED DRUG; CDKN1A PROTEIN, MOUSE; CDKN1B PROTEIN, MOUSE; CELL CYCLE PROTEIN; CELL RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLINE; ENZYME INHIBITOR; FLAVONOID; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; IMMUNOBLOTTING; MESANGIUM CELL; MOUSE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SERUM RESPONSIVE ELEMENT; SIGNAL TRANSDUCTION; ANIMAL; CELL DIVISION; CYTOLOGY; DRUG POTENTIATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; MESANGIUM; METABOLISM; ONCOGENE; PHOSPHORYLATION; PHYSIOLOGY;

ANIMALS; CELL CYCLE PROTEINS; CELL DIVISION; CELLS, CULTURED; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLINS; DRUG SYNERGISM; ENZYME INHIBITORS; FLAVONOIDS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENES, FOS; GLOMERULAR MESANGIUM; LIGANDS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLATELET-DERIVED GROWTH FACTOR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SERUM RESPONSE ELEMENT; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0038130698     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00054.x     Document Type: Article

References (40)

1. CYBULSKY AV: Growth factor pathways in proliferative glomerulonephritis. Curr Opin Nephrol Hypertens 9:217-223, 2000
2. WILSON CB: Immune models of glomerular injury, in Immunological Renal Diseases, edited by NEILSON EG, COUSER WG, Philadelphia, Lippincott-Raven Publishers, pp 729-773, 1997
3. STERZEL RB, RUPPRECHT HD: Glomerular mesangial cells, in Immunological Renal Diseases, edited by NEILSON EG, COUSER WG, Philadelphia, Lippincott-Raven Publishers, pp 595-626, 1997
4. GILLE H, KORTENJANN M, STRAHL T, et al: Phosphorylation-dependent formation of a quaternary complex at the c-fos SRE. Mol Cell Biol 16:1094-1102, 1996
5. LOTFI CF, ARMELIN HA: Cfos and cjun antisense oligonucleotides block mitogenesis triggered by fibroblast growth factor-2 and ACTH in mouse Y1 adrenocortical cells. J Endocrinol 168:381-389, 2001
6. SCHREIBER M, BAUMANN B, COTTEN M, et al: Fos is an essential component of the mammalian UV response. EMBO J 14:5338-5449, 1995
7. HILL CS, TREISMAN R: Differential activation of c-fos promoter elements by serum, lysophosphatidic acid. G EMBO J 14:5037-5047, 1995
8. JANKNECHT R, CAHIL MA, NORDHEM A: Signal integration at the c-fos promoter. Carcinogenesis 16:443-450, 1995
9. NAKANO K, CHIJIIWA K, TANAKA M: Lower activity of CCAAT/enhancer-binding protein and expression of cyclin E, but not cyclin D1, activating protein-1 and p21(WAF1), after partial hepatectomy in obstructive jaundice. Biochem Biophys Res Commun 280:640-645, 2001
10. ALBANESE C, JOHNSON J, WATANABE G, et al: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270:23589-23597, 1995
11. GUAN Y, BREYER MD: Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int 60:14-30, 2001
12. ASANO T, WAKISAKA M, YOSHINARI M, et al: Peroxisome proliferator-activated receptor gammal (PPARgammal) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation. Biochim Biophys Acta 1497:148-154, 2000
13. BRAISSANT O, FOUFELLE F, SCOTTO C, et al: Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology 137:354-366, 1996
14. MCCARTHY KJ, ROUTH RE, SHAW W, et al: Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58:2341-2350, 2000
15. AHMED SA, GOGAL RM, JR, WALSH JE: A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: An alternative to [3H]thymidine incorporation assay. J Immunol Methods 170:211-224, 1994
16. DE FRIES R, MITSUHASHI M; Quantification of mitogen induced human lymphocyte proliferation: Comparison of alamar Blue assay to 3H-thymidine incorporation assay. J Clin Lab Anal 9:89-95, 1995
17. LYALL V, ALAM RI, PHAN TT, et al: Modulation of rat chorda tympani NaCl responses and intracellular Na+ activity in polarized taste receptor cells by pH. J Gen Physiol 120:1-23, 2002
18. LANG S, HARTNER A, STERZEL RB. et al: Requirement of cyclin D1 in mesangial cell mitogenesis. J Am Soc Nephrol 11:1398-1408, 2000
19. COATES G, NISSIM I, BATTARBEE H, et al: Glitazones regulate glutamine metabolism by inducing a cellular acidosis in MDCK cells. Am J Physiol Endocrinol Metab 283:E729-737, 2002
20. DE DIOS ST, HANNAN KM, DILLEY RJ, et al: Troglitazone, but not rosiglitazone, inhibits Na/H exchange activity and proliferation of macrovascular endothelial cells. J Diabetes Complications 15:120-127, 2001
21. SCHRAMEK H, SCHUMACHER M, PFALLER W: Sustained ERK-2 activation in rat glomerular mesangial cells: differential regulation by protein phosphatases. Am J Physiol 271(2 Pt 2):F423-432, 1996
22. SHERR CJ, ROBERTS JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13:1501-1512, 1999
23. SHANKLAND SJ, WOLF G: Cell cycle regulatory proteins in renal disease: Role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol 278:F515-29, 2000
24. PALAKURTHI SS, AKTAS H, GRUBISSICH LM, et al: Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 61:6213-6218, 2001
25. CAMP HS, LI O, WISE SC, et al: Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 49:539-547, 2000
26. HUNTER JG, VAN DELFT MF, RACHUBINSKI RA, et al: Peroxisome proliferator-activated receptor gamma ligands differentially modulate muscle cell differentiation and MyoD gene expression via peroxisome proliferator-activated receptor gamma-dependent and-independent pathways. J Biol Chem 276:38297-38306, 2001
27. MARRA F, ARRIGHI MC, FAZI M, et al: Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 4:951-958, 1999
28. PAGES GP, LENORMAND G, L'ALLEMAIN J, et al: Mitogen-activated protein kinase p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 90:8319-8323, 1993
29. HATTORI Y, AKIMOTO K, KASAI K: The effects of thiazolidinediones on vascular smooth muscle cell activation by angiotensin II. Biochem Biophys Res Commun 273:1144-1149, 2000
30. KOVARY K, BRAVO R: The jun and fos protein families are both required for cell cycle progression in fibroblasts. Mol Cell Biol 11:4466-4472, 1991
31. COOK SJ, AZIZ N, MCMAHON M: The repertoire of fos and jun proteins expressed during the G1 phase of the cell cycle is determined by the duration of mitogen-activated protein kinase activation. Mol Cell Biol 19:330-341, 1999
32. LAW RE, MEEHAN WP, XI XP, et al: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897-1905, 1996
33. MIAO GG, CURRAN T: Cell transformation by c-fos requires an extended period of expression and is independent of the cell cycle. Mol Cell Biol 14:4295-4431, 1994
34. BROWN JR, NIGH E, LEE RJ, et al: Fos family members induce cell cycle entry by activating cyclin D1. Mol Cell Biol 18:5609-5619, 1998
35. WAKINO S, KINTSCHER U, KIM S, et al: Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→ S transition in vascular smooth muscle cells. J Biol Chem 21:22435-22441, 2000
36. SHANKLAND SJ, PIPPIN J, FLANAGAN M, et al: Mesangial cell proliferation mediated by PDGF and bFGF is determined by levels of the cyclin kinase inhibitor p27Kip1. Kidney Int 51:1088-1099, 1997
37. SUBBARAMAIAH K, LIN DT, HART JC, et al: Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 276:12440-12448, 2001
38. BISHOP-BAILEY D, HLA T: Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J Biol Chem 274:17042-17048, 1999
39. SCHRAMEK H, SOROKIN A, WATSON RD, et al: Differential long-term regulation of MEK and of p42 MAPK in rat glomerular mesangial cells. Am J Physiol 270(1 Pt 1):C40-48 1996
40. HOSHINO R, TANIMURA S, WATANABE K, et al: Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27(Kip1). J Biol Chem 276:2686-2692, 2001